As of the most recent data (June 2024), TCBPW shows a EBIT of $-24M. That compares with $-2.1M in the prior-year period — down 1054.2% year over year. That is below the sector sector average of $-22M. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TCBPW's EBIT is now $-24M (was $-2.1M) — a 1054.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether TC BioPharm (Holdings) plc - Warrants (08/02/2027) is outperforming or lagging.

The its sector sector average EBIT is about $-22M. TC BioPharm (Holdings) plc - Warrants (08/02/2027) is at $-24M, which is lower that average. That is roughly 13.7% below the sector mean. Use the comparison chart on this page to see how TCBPW stacks up against individual peers as well.

Tracking TCBPW's ebit over time shows whether TC BioPharm (Holdings) plc - Warrants (08/02/2027) is scaling, shrinking, or reshaping that part of the business. The current reading is $-24M That compares with $-2.1M in the prior-year period — down 1054.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has TC BioPharm (Holdings) plc - Warrants (08/02/2027)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-24M) with ownership activity and broader fundamentals.